The estimated Net Worth of George Cardoza is at least $12.1 Milion dollars as of 2 June 2021. Mr. Cardoza owns over 200,337 units of Neogenomics stock worth over $2,883,151 and over the last 11 years he sold NEO stock worth over $8,156,798. In addition, he makes $1,107,370 as President - Pharma Services Division at Neogenomics.
George has made over 12 trades of the Neogenomics stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 200,337 units of NEO stock worth $8,083,598 on 2 June 2021.
The largest trade he's ever made was selling 200,337 units of Neogenomics stock on 2 June 2021 worth over $8,083,598. On average, George trades about 47,445 units every 114 days since 2013. As of 2 June 2021 he still owns at least 176,772 units of Neogenomics stock.
You can see the complete history of Mr. Cardoza stock trades at the bottom of the page.
George A. Cardoza serves as President - Pharma Services Division of the Company. Mr. Cardoza has served the Company as the President of Pharma Services since March 2018. He has been with NeoGenomics since November 2009, serving as the Company’s Chief Financial Officer through March 2018. Prior to that, he was the Chief Financial Officer at Protocol Integrated Direct Marketing. Mr. Cardoza spent fifteen years with Quest Diagnostics, including years when it was still part of Corning Inc. With Corning Inc. he worked with the Corning Life Sciences Division, which did several acquisitions in the Pharma services space. These acquisitions formed the pieces of Covance, which Corning spun out at the same time as Quest in 1996. Mr. Cardoza has worked closely with NeoGenomics Pharmaceutical Services and Clinical Trials division, which was combined into the Clinical Trials arm of Clarient Inc. when it was acquired from General Electric Healthcare in December 2015. Mr. Cardoza received his B.S. from Syracuse University in finance and accounting and has received his M.B.A. from Michigan State University.
As the President - Pharma Services Division of Neogenomics, the total compensation of George Cardoza at Neogenomics is $1,107,370. There are 3 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
George Cardoza is 58, he's been the President - Pharma Services Division of Neogenomics since 2018. There are 10 older and 15 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
George's mailing address filed with the SEC is 9490 NEOGENOMICS WAY, , FORT MYERS, FL, 33912.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van a Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: